<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 的股票在周五交易前因内部人士卖出活动而出现跳空下跌。该股此前收于 43.96 美元，但开盘价为 42.91 美元。Hims
&amp; Hers Health 的股票最后交易价格为 44.71 美元，成交量为 4,937,687 股。</p>
<ul>
<li>奥泽姆比热潮：Hims
&amp; 艾利 Lilly 引领医疗保健投资</li>
</ul>
<p>具体来说，首席执行官安德鲁·杜杜姆在 8 月 18 日星期一的交易中出售了 128,127 股公司的股票。这些股票以平均价格 45.06 美元出售，总价值为 5,773,402.62 美元。出售完成后，首席执行官直接持有公司 89,521 股股票，价值 4,033,816.26 美元。此次交易使其持股比例减少了 58.87%。该出售在与证券交易委员会的法律文件中披露，相关文件可通过此链接获取。</p>
<p>获取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
<h2>分析师升级和降级</h2>
<p>HIMS 已成为多份研究报告的主题。Zacks Research 在周二的报告中将 Hims
&amp; Hers Health 的股票评级从 “强力买入” 下调至 “持有”。Needham
&amp; Company LLC 在 8 月 5 日的报告中重申了对 Hims
&amp; Hers Health 股票的 “持有” 评级。德意志银行在 5 月 7 日的报告中重申了对 Hims
&amp; Hers Health 股票的 “持有” 评级。花旗集团在 6 月 23 日的报告中重申了对 Hims
&amp; Hers Health 股票的 “卖出” 评级。最后，TD Cowen 在 4 月 29 日的研究报告中将 Hims
&amp; Hers Health 的股票评级从 “买入” 下调至 “持有”，并将其股票目标价从 44.00 美元下调至 30.00 美元。两位股票研究分析师给予该股 “买入” 评级，八位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “减持”，共识目标价为 38.92 美元。</p>
<ul>
<li>内部人士在与 NVIDIA 相关的 Navitas、Hims
&amp; Shift4 中交易数百万</li>
</ul>
<p><strong>阅读我们对 HIMS 的最新分析</strong></p>
<h2>Hims</h2>
<p>&amp; Hers Health 股票上涨 1.2%</p>
<p>该公司的债务与股本比率为 1.72，流动比率为 4.98，速动比率为 4.46。该公司的市值为 100.5 亿美元，市盈率为 55.57，市盈增长比率为 2.93，贝塔值为 2.08。该公司的 50 日移动平均价格为 51.92 美元，200 日移动平均价格为 45.76 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 08/04 - 08/08</li>
</ul>
<p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近于 8 月 4 日星期一发布了季度财报。该公司报告本季度每股收益（EPS）为 0.17 美元，低于共识预期的 0.18 美元（差额为 0.01 美元）。该公司本季度的收入为 5.4483 亿美元，而分析师预期为 5.5006 亿美元。Hims
&amp; Hers Health 的股本回报率为 26.26%，净利润率为 9.63%。Hims
&amp; Hers Health 的收入同比增长 72.6%。在去年同期，该公司每股收益为 0.06 美元。Hims
&amp; Hers Health 已设定 2025 年第三季度的指引为每股收益。2025 财年的指引为每股收益。卖方分析师预计 Hims
&amp; Hers Health, Inc. 本年度将发布 0.29 美元的每股收益。</p>
<h2>Hims</h2>
<p>&amp; Hers Health 的机构交易</p>
<p>一些对冲基金和其他机构投资者最近对该股票的持仓进行了调整。Marex Group plc 在第二季度购买了 Hims
&amp; Hers Health 的新股份，价值约为 53,626,000 美元。野村控股公司在第二季度将其在 Hims
&amp; Hers Health 的股份增加了 151.4%。野村控股公司现在拥有 161,052 股该公司的股票，价值 8,028,000 美元，此前在上一季度购买了额外的 96,997 股。Castleark Management LLC 在第二季度收购了 Hims
&amp; Hers Health 的新股份，价值约为 2,921,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Hims
&amp; Hers Health 的股份增加了 54.3%。Tower Research Capital LLC TRC 现在拥有 38,285 股该公司的股票，价值 1,909,000 美元，此前在上一季度购买了额外的 13,473 股。最后，SkyView Investment Advisors LLC 在第二季度收购了 Hims
&amp; Hers Health 的新股份，价值约为 226,000 美元。目前 63.52% 的股票由机构投资者持有。</p>
<h2>Hims</h2>
<p>&amp; Hers Health 公司简介</p>
<p>(获取免费报告)</p>
<p>Hims
&amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病学和初级保健的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比 Hims
&amp; Hers Health 更好</li>
<li>为什么股票行业对成功投资很重要？</li>
<li>小型股，大潜力：您应该了解的三家科技颠覆者</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>在财报未达预期后，沃尔玛仍然是顶级消费品投资选择</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>思科如何为投资者构建新的增长故事</li>
</ul>
<p><em>此即时新闻提醒是通过叙述科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
<h2>您现在应该投资 1,000 美元在 Hims</h2>
<p>&amp; Hers Health 吗？</p>
<p>在您考虑 Hims
&amp; Hers Health 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已确定五只股票，顶级分析师正在悄悄地向客户推荐购买，以便在更广泛的市场注意到之前... 而 Hims
&amp; Hers Health 并不在名单上。</p>
<p>尽管 Hims &amp; Hers Health 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

<p>Hims & Hers Health（纽约证券交易所代码：HIMS）股价因首席执行官 Andrew Dudum 的内部出售而跳空下跌至 42.91 美元，他以每股 45.06 美元的价格出售了 128,127 股。该股收盘价为 44.71 美元，交易量接近 500 万股。分析师已下调该股评级，Zacks 将其评级从 “强力买入” 调整为 “持有”。公司报告第二季度每股收益为 0.17 美元，未达到预期，营收为 5.4483 亿美元，同比增长 72.6%。机构投资者持有该股 63.52% 的股份</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares gapped down prior to trading on Friday following insider selling activity. The stock had previously closed at $43.96, but opened at $42.91. Hims &amp; Hers Health shares last traded at $44.71, with a volume of 4,937,687 shares changing hands.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 的股票在周五交易前因内部人士卖出活动而出现跳空下跌。该股此前收于 43.96 美元，但开盘价为 42.91 美元。Hims
&amp; Hers Health 的股票最后交易价格为 44.71 美元，成交量为 4,937,687 股。</p>
</div><ul>
<li>Ozempic Boom: Hims &amp; Eli Lilly Lead Healthcare Bets</li>
</ul>
<div class="lb-trans"><ul>
<li>奥泽姆比热潮：Hims
&amp; 艾利 Lilly 引领医疗保健投资</li>
</ul>
</div><p>Specifically, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $45.06, for a total value of $5,773,402.62. Following the completion of the sale, the chief executive officer directly owned 89,521 shares of the company's stock, valued at $4,033,816.26. The trade was a 58.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink.</p>
<div class="lb-trans"><p>具体来说，首席执行官安德鲁·杜杜姆在 8 月 18 日星期一的交易中出售了 128,127 股公司的股票。这些股票以平均价格 45.06 美元出售，总价值为 5,773,402.62 美元。出售完成后，首席执行官直接持有公司 89,521 股股票，价值 4,033,816.26 美元。此次交易使其持股比例减少了 58.87%。该出售在与证券交易委员会的法律文件中披露，相关文件可通过此链接获取。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>HIMS has been the subject of a number of research reports. Zacks Research cut shares of Hims &amp; Hers Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a report on Tuesday, August 5th. Deutsche Bank Aktiengesellschaft reaffirmed a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a report on Wednesday, May 7th. Citigroup reaffirmed a &#34;sell&#34; rating on shares of Hims &amp; Hers Health in a report on Monday, June 23rd. Finally, TD Cowen lowered shares of Hims &amp; Hers Health from a &#34;buy&#34; rating to a &#34;hold&#34; rating and dropped their price target for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of &#34;Reduce&#34; and a consensus target price of $38.92.</p>
<div class="lb-trans"><p>HIMS 已成为多份研究报告的主题。Zacks Research 在周二的报告中将 Hims
&amp; Hers Health 的股票评级从 “强力买入” 下调至 “持有”。Needham
&amp; Company LLC 在 8 月 5 日的报告中重申了对 Hims
&amp; Hers Health 股票的 “持有” 评级。德意志银行在 5 月 7 日的报告中重申了对 Hims
&amp; Hers Health 股票的 “持有” 评级。花旗集团在 6 月 23 日的报告中重申了对 Hims
&amp; Hers Health 股票的 “卖出” 评级。最后，TD Cowen 在 4 月 29 日的研究报告中将 Hims
&amp; Hers Health 的股票评级从 “买入” 下调至 “持有”，并将其股票目标价从 44.00 美元下调至 30.00 美元。两位股票研究分析师给予该股 “买入” 评级，八位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “减持”，共识目标价为 38.92 美元。</p>
</div><ul>
<li>Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, &amp; Shift4</li>
</ul>
<div class="lb-trans"><ul>
<li>内部人士在与 NVIDIA 相关的 Navitas、Hims
&amp; Shift4 中交易数百万</li>
</ul>
</div><p><strong>Read Our Latest Analysis on HIMS</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 HIMS 的最新分析</strong></p>
</div><h2>Hims &amp; Hers Health Stock Up 1.2%</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 股票上涨 1.2%</p>
</div><p>The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The firm has a market capitalization of $10.05 billion, a price-to-earnings ratio of 55.57, a price-to-earnings-growth ratio of 2.93 and a beta of 2.08. The firm's 50-day moving average price is $51.92 and its 200 day moving average price is $45.76.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 1.72，流动比率为 4.98，速动比率为 4.46。该公司的市值为 100.5 亿美元，市盈率为 55.57，市盈增长比率为 2.93，贝塔值为 2.08。该公司的 50 日移动平均价格为 51.92 美元，200 日移动平均价格为 45.76 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 08/04 - 08/08</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 08/04 - 08/08</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims &amp; Hers Health had a return on equity of 26.26% and a net margin of 9.63%.Hims &amp; Hers Health's revenue was up 72.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.06 EPS. Hims &amp; Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts expect that Hims &amp; Hers Health, Inc. will post 0.29 EPS for the current year.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近于 8 月 4 日星期一发布了季度财报。该公司报告本季度每股收益（EPS）为 0.17 美元，低于共识预期的 0.18 美元（差额为 0.01 美元）。该公司本季度的收入为 5.4483 亿美元，而分析师预期为 5.5006 亿美元。Hims
&amp; Hers Health 的股本回报率为 26.26%，净利润率为 9.63%。Hims
&amp; Hers Health 的收入同比增长 72.6%。在去年同期，该公司每股收益为 0.06 美元。Hims
&amp; Hers Health 已设定 2025 年第三季度的指引为每股收益。2025 财年的指引为每股收益。卖方分析师预计 Hims
&amp; Hers Health, Inc. 本年度将发布 0.29 美元的每股收益。</p>
</div><h2>Institutional Trading of Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 的机构交易</p>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Marex Group plc bought a new stake in shares of Hims &amp; Hers Health during the 2nd quarter worth about $53,626,000. Nomura Holdings Inc. grew its stake in shares of Hims &amp; Hers Health by 151.4% in the 2nd quarter. Nomura Holdings Inc. now owns 161,052 shares of the company's stock worth $8,028,000 after purchasing an additional 96,997 shares during the last quarter. Castleark Management LLC acquired a new position in shares of Hims &amp; Hers Health in the 2nd quarter worth approximately $2,921,000. Tower Research Capital LLC TRC grew its stake in shares of Hims &amp; Hers Health by 54.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 38,285 shares of the company's stock worth $1,909,000 after purchasing an additional 13,473 shares during the last quarter. Finally, SkyView Investment Advisors LLC acquired a new position in shares of Hims &amp; Hers Health in the 2nd quarter worth approximately $226,000. 63.52% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该股票的持仓进行了调整。Marex Group plc 在第二季度购买了 Hims
&amp; Hers Health 的新股份，价值约为 53,626,000 美元。野村控股公司在第二季度将其在 Hims
&amp; Hers Health 的股份增加了 151.4%。野村控股公司现在拥有 161,052 股该公司的股票，价值 8,028,000 美元，此前在上一季度购买了额外的 96,997 股。Castleark Management LLC 在第二季度收购了 Hims
&amp; Hers Health 的新股份，价值约为 2,921,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Hims
&amp; Hers Health 的股份增加了 54.3%。Tower Research Capital LLC TRC 现在拥有 38,285 股该公司的股票，价值 1,909,000 美元，此前在上一季度购买了额外的 13,473 股。最后，SkyView Investment Advisors LLC 在第二季度收购了 Hims
&amp; Hers Health 的新股份，价值约为 226,000 美元。目前 63.52% 的股票由机构投资者持有。</p>
</div><h2>Hims &amp; Hers Health Company Profile</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 公司简介</p>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病学和初级保健的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Small Cap, Big Potential: 3 Tech Disruptors You Should Know About</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>After Earnings Miss, Walmart Is Still a Top Consumer Staples Play</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>How Cisco Is Building a New Growth Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Hims
&amp; Hers Health 更好</li>
<li>为什么股票行业对成功投资很重要？</li>
<li>小型股，大潜力：您应该了解的三家科技颠覆者</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>在财报未达预期后，沃尔玛仍然是顶级消费品投资选择</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>思科如何为投资者构建新的增长故事</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是通过叙述科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Hims</h2>
<p>&amp; Hers Health 吗？</p>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Hims
&amp; Hers Health 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已确定五只股票，顶级分析师正在悄悄地向客户推荐购买，以便在更广泛的市场注意到之前... 而 Hims
&amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Hims &amp; Hers Health 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Hims & Hers Health（纽约证券交易所代码：HIMS）的股票在内部人士抛售后出现跳空低开